Journal
JACC: CARDIOONCOLOGY
Volume 2, Issue 3, Pages 385-396Publisher
ELSEVIER
DOI: 10.1016/j.jaccao.2020.07.008
Keywords
acute coronary syndromes; cancer; ezetimibe; lipid-lowering therapy; lipids; malignancy; statin
Categories
Funding
- Merck
- Amgen
- Geneva University Hospitals
- Eugenio Litta
- Athemis Foundations
- Arena
- AstraZeneca
- Bristol-Myers Squibb
- Daiichi-Sankyo
- Eisai
- Eli Lilly
- Janssen
- Sanofi
- Brigham and Women's Hospital: Abbott
- Brigham and Women's Hospital: Amgen
- Brigham and Women's Hospital: Aralez
- Brigham and Women's Hospital: AstraZeneca
- Brigham and Women's Hospital: Bayer HealthCare Pharmaceuticals, Inc.
- Brigham and Women's Hospital: BRAHMS
- Brigham and Women's Hospital: Daiichi-Sankyo
- Brigham and Women's Hospital: Eisai
- Brigham and Women's Hospital: GlaxoSmithKline
- Brigham and Women's Hospital: Intarcia
- Brigham and Women's Hospital: Janssen
- Brigham and Women's Hospital: MedImmune
- Brigham and Women's Hospital: Merck
- Brigham and Women's Hospital: Novartis
- Brigham and Women's Hospital: Pfizer
- Brigham and Women's Hospital: Poxel
- Brigham and Women's Hospital: Quark Pharmaceuticals
- Brigham and Women's Hospital: Roche
- Brigham and Women's Hospital: Takeda
- Brigham and Women's Hospital: The Medicines Company
- Brigham and Women's Hospital: Zora Biosciences
- DaiichiSankyo
- Novartis
Ask authors/readers for more resources
BACKGROUND An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. OBJECTIVES The purpose of this study was to clarify this unexpected finding in a larger sample size of patients stabilized after acute coronary syndrome, we conducted a prospective systematic analysis of malignancy events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). METHODS Within IMPROVE-IT, 17,708 patients post-acute coronary syndrome were randomized to either ezetimibe 10 mg or matching placebo on a background of simvastatin 40 mg who took $1 dose of the study drug. Suspected tumors (benign and malignant) reported by investigators or identified from a review of adverse events were adjudicated by oncologists without knowledge of drug assignment. The primary malignancy endpoint included new, relapsing, or progressive malignancies (excluding nonmelanotic skin malignancies). The secondary endpoint was death due to malignancy. RESULTS In this trial, 1,470 patients developed the primary malignancy endpoint during a median 6 years of follow-up. The most common malignancy locations were prostate (18.9%), lung (16.8%), and bladder (8.8%) with no differences by treatment group (p > 0.05 for each location). Kaplan-Meier 7-year rates of malignancies were similar with ezetimibe and placebo (10.2% vs. 10.3%; hazard ratio: 1.03; 95% confidence interval: 0.93 to 1.14; p = 0.56), as were the rates for malignancy death (3.8% vs. 3.6%; hazard ratio: 1.04; 95% confidence interval: 0.88 to 1.23; p = 0.68). CONCLUSIONS Among 17,708 patients receiving simvastatin 40 mg daily, those randomized to ezetimibe 10 mg daily had a similar incidence of malignancy and deaths due to malignancy compared with those receiving placebo during a median follow-up of 6 years (96,377 patient-years). (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available